Cross-resistance of human multidrug-resistant cells to mitomycin C
- PMID: 1909515
Cross-resistance of human multidrug-resistant cells to mitomycin C
Abstract
Human multidrug-resistant cells, K562/ADM, KB-C-4, AdrRMCF-7 and CEM/VLB100 showed 21-, 7.5-, 105- and 3.4-fold cross-resistance to mitomycin C (MMC). The resistance to MMC in K562/ADM, KB-C-4, AdrRMCF-7, CEM/VLB100 cells was reversed by 6.6 microM verapamil. Accumulation of [3H]MMC in K562/ADM, AdrRMCF-7 and CEM/VLB100 cells also decreased by 37, 26 and 33%, as compared with their drug-sensitive counterparts. In KB-C-4 cells, accumulation of [3H]MMC decreased by 60%, and efflux rate of [3H]MMC was slightly increased as compared to their parental KB-3-1 cells. Verapamil at 6.6 microM increased accumulation of [3H]MMC in these multidrug-resistant sublines. K562/ADM10, K562/ADM50, K562/ADM100 and K562/ADM250 cells, which showed 17- to 230-fold resistance to Adriamycin, also showed 0.8- to 7.3-fold cross-resistance to MMC. In these cell lines, the extent of resistance to Adriamycin (ADM) that was consistent with expression levels of P-glycoprotein shown by immunoblotting was directly proportional to the extent of their resistance to MMC. Regression analysis indicated that relative resistance to Adriamycin was correlated with relative resistance to MMC (r = 0.98). These results indicate that MMC can be transported by P-glycoprotein overexpressed in multidrug-resistant cells.
Similar articles
-
In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.Cancer Res. 1989 Aug 1;49(15):4098-102. Cancer Res. 1989. PMID: 2472873
-
Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells.Cancer Res. 1991 Jan 1;51(1):157-61. Cancer Res. 1991. PMID: 1988080
-
Mr 85,000 membrane protein specifically expressed in adriamycin-resistant human tumor cells.Cancer Res. 1988 Dec 15;48(24 Pt 1):7082-7. Cancer Res. 1988. PMID: 2903793
-
New findings in the pharmacokinetic, metabolic, and drug-resistance aspects of mitomycin C.Semin Oncol. 1988 Jun;15(3 Suppl 4):32-41. Semin Oncol. 1988. PMID: 3134696 Review.
-
Free radicals and anticancer drug resistance: oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors.Free Radic Biol Med. 1990;8(6):567-81. doi: 10.1016/0891-5849(90)90155-c. Free Radic Biol Med. 1990. PMID: 2113883 Review.
Cited by
-
Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophageal cancer.J Clin Pathol. 1995 Nov;48(11):1064-6. doi: 10.1136/jcp.48.11.1064. J Clin Pathol. 1995. PMID: 8543635 Free PMC article.
-
Assay-based response evaluation in head and neck oncology: requirements for better decision making.Eur Arch Otorhinolaryngol. 2010 Apr;267(4):483-94. doi: 10.1007/s00405-009-1191-5. Epub 2010 Jan 6. Eur Arch Otorhinolaryngol. 2010. PMID: 20052589